...
首页> 外文期刊>Academic radiology >Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels.
【24h】

Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels.

机译:血清前列腺特异性抗原水平升高的男性对比增强的灰度经直肠超声引导下的前列腺活检。

获取原文
获取原文并翻译 | 示例
           

摘要

RATIONALE AND OBJECTIVES: Our goal was to evaluate the role of contrast-enhanced gray-scale transrectal ultrasound (CETRUS)-guided prostate biopsy in patients with elevated serum prostate-specific antigen (PSA) levels. MATERIALS AND METHODS: A total of 115 men (mean age, 70 years; range, 47-85) with serum PSA levels of greater than 4.0 ng/ml were assessed using gray-scale transrectal ultrasound (TRUS), power Doppler ultrasound (PDU), and CETRUS. Subsequently, these patients underwent systematic sextant transrectal biopsy and additional biopsies for positive sites on gray-scale TRUS, PDU, and CETRUS. The cancer detection rates of the three techniques were compared. RESULTS: Cancer was detected in 63 of the 115 patients (55%). CETRUS was positive in 50 patients, 35 of whom (70%) had prostate cancer; CETRUS had a higher sensitivity, specificity, and accuracy of 65% (41/63), 83% (43/52), and 73% (84/115), respectively. CETRUS could have saved a significant number of patients from undergoing unnecessary biopsies, compared to TRUS and PDU. However, no significant correlation was found between the Gleason score and CETRUS grade. CONCLUSIONS: The use of CETRUS in detecting prostate cancer might reduce the number of unnecessary needle biopsies of the prostate in patients with abnormally high serum PSA levels and increase the detection rate of clinically significant prostate cancer.
机译:理由和目的:我们的目标是评估在血清前列腺特异性抗原(PSA)水平升高的患者中,增强造影剂灰度经直肠超声(CETRUS)指导的前列腺穿刺活检的作用。材料与方法:采用灰度经直肠超声(TRUS),功率多普勒超声(PDU)对115名男性(平均年龄70岁;范围47-85)的血清PSA水平大于4.0 ng / ml进行了评估。 )和CETRUS。随后,这些患者接受了系统的六分点经直肠穿刺活检,并进行了其他活检,以检查灰阶TRUS,PDU和CETRUS上的阳性部位。比较了三种技术的癌症检出率。结果:115例患者中有63例被检测出癌症(55%)。 50例患者中CETRUS呈阳性,其中35例(70%)患有前列腺癌。 CETRUS的敏感性,特异性和准确性更高,分别为65%(41/63),83%(43/52)和73%(84/115)。与TRUS和PDU相比,CETRUS可以使大量患者免于不必要的活检。然而,在格里森评分和CETRUS评分之间未发现显着相关性。结论:使用CETRUS检测前列腺癌可以减少血清PSA水平异常高的患者不必要的前列腺穿刺活检次数,并提高具有临床意义的前列腺癌的检出率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号